Rosetta Genomics Completes Acquisition of Parkway Clinical Laborat...(otein activity through microRNAs could p...)

Date:7/24/2008

otein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the completion of the acquisition of Parkway by Rosetta and the expected impact of the acquisition will have on the commercialization of Rosetta's microRNA-based diagnostics, Parkway's expected revenues and operating income for 2008, the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of the development and commercialization of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially fr
'/>"/>

SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
2. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
3. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
4. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
5. /C O R R E C T I O N -- Rosetta Genomics Ltd/
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
8. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
9. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
10. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
11. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents